<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
As the prospects for its once-promising Alzheimer’s drug continue to dim, Biogen Inc. ( BIIB , Financial) is reportedly exploring strategic options, including selling itself or acquiring a smaller bioscience company. The Boston-area biotech has gone so far as to hire Goldman Sachs Group Inc. ( GS , Financial) to put together a roster of potential acquisition targets, Stat reports, citing a person familiar with the companies’ relationships.
...read full article on GuruFocus
